Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Personalis's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Personalis's regulatory disclosures and financial reporting.
Ameriprise Financial, Inc. filed a Schedule 13G reporting a significant ownership stake in Personalis, Inc. common stock. As of 12/31/2025, Ameriprise reports beneficial ownership of 6,287,151 shares, representing 7.1% of Personalis’ outstanding common stock.
Ameriprise reports no sole voting or dispositive power, with all reported voting and dispositive power shared across these holdings. The firm states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Personalis, and disclaims beneficial ownership of the shares reported.
Tempus AI, Inc., a 10% owner of Personalis, Inc., reported a series of open-market purchases of Personalis common stock. Between November 18 and December 22, 2025, Tempus AI bought multiple blocks of shares at weighted-average prices generally between $7.67 and $11.00, as detailed in the transaction table and footnotes.
After the latest reported trade on December 22, 2025, Tempus AI beneficially owned 13,039,067 shares of Personalis common stock, held directly. The footnotes explain that each reported price is a weighted average for numerous trades within stated intraday price ranges.
Personalis, Inc. investor Orin Hirschman and affiliated AIGH entities report a passive ownership position below 5% of the company’s common stock. The filing shows Mr. Hirschman beneficially owning 3,416,720 shares, representing 3.8% of the outstanding common stock, with sole voting and dispositive power.
AIGH Capital Management LLC separately reports beneficial ownership of 2,900,000 shares, or 3.3% of the class, also with sole voting and dispositive power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Personalis.
Personalis, Inc. insider trading report: Chief Financial Officer and Chief Operating Officer Aaron Tachibana exercised stock options for 1,201 shares of common stock at $9.16 per share on January 22, 2026, then sold 1,201 shares of common stock at $11.50 per share the same day. After these transactions, he held 164,458 shares of common stock directly and 107,631 stock options. The filing notes that the sale and option exercise were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, which is designed to allow insiders to trade shares according to a set schedule.
A shareholder has filed a notice of proposed sale for 40,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/22/2026. The filing lists an aggregate market value of 386,000.00 for these shares and identifies the securities as listed on NASDAQ. The shares to be sold were acquired on 01/22/2026 via an exercise of stock options, paid for in cash on the same date. Over the prior three months, the filing reports that 103,668 common shares were sold for gross proceeds of 1,117,065.47 in Rule 10b5-1 sales for AARON L TACHIBANA.
T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting a significant passive stake in Personalis Inc. (PSNL). The firm reports beneficial ownership of 10,780,290 shares of Personalis common stock, representing 12.1% of the class as of the event date of 12/31/2025. T. Rowe Price Investment Management is identified as an investment adviser and reports sole voting and dispositive power over all of these shares, with no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Personalis, and it expressly denies that T. Rowe Price Investment Management should be deemed the beneficial owner of the securities.
Personalis, Inc. reported that it has released certain preliminary financial and operational results for the quarter and fiscal year ended December 31, 2025. These results were announced through a press release dated January 8, 2026.
The company furnished the full text of this press release as Exhibit 99.1 to the current report, incorporating it by reference for informational purposes. The information in this report, including Exhibit 99.1, is provided under special Exchange Act provisions so it is not treated as formally filed or automatically incorporated into other securities law filings unless specifically referenced.
Personalis, Inc. announced that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has revised its Medicare reimbursement rates for the company’s ultrasensitive NeXT Personal® test used to monitor cancer recurrence in stage II and III breast cancer patients. Effective December 1, 2025, the NeXT Personal Dx Breast MRD Recurrence Monitoring Test will be reimbursed at $4,266 and the NeXT Personal Single Plasma Test at $1,164. Medicare will cover the Dx Breast MRD Recurrence Monitoring Test once per cancer diagnosis, while the Single Plasma Test is covered for up to six years after treatment, shaping how often these tests can be used for long-term patient surveillance.
Personalis (PSNL) announced that its ultrasensitive NeXT Personal tests received Medicare coverage for post‑treatment surveillance of cancer recurrence in stage II and III breast cancer. The determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program is effective retroactively as of October 7, 2025.
The NeXT Personal Dx Breast MRD Recurrence Monitoring Test is covered at a reimbursement rate of $3,878 and is available once per cancer diagnosis. The NeXT Personal Single Plasma Test is covered at $1,158 and is available for up to six years post‑treatment. This expands access and establishes defined payment levels for these assays among eligible Medicare patients.
Personalis, Inc. (PSNL) reported an insider transaction by its President and CEO. On 11/03/2025, the reporting person sold 29,612 shares of common stock at a weighted average price of $8.99, with individual sale prices ranging from $8.78 to $9.56. The filing states the shares were automatically sold to cover tax withholding from the settlement of vested restricted stock units. Following the transaction, the reporting person beneficially owned 148,486 shares directly.